Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical TrailsPosted by saikrishna on May 28th, 2018 Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018Acute Lymphoblastic Leukemia Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018 Overview: Acute Lymphoblastic Leukemia is a type of cancer which affects white blood cells. It is also called as Acute lymphocytic leukemia. IALL progresses rapidly without treatment. Acute lymphoblastic leukemia (ALL) is a malignant (clonal) disease of the bone marrow in which early lymphoid precursors proliferate and replace the normal hematopoietic cells of the marrow. Symptoms of ALL includes fever, anemia, bleeding, blood clots, bone pain, rashes on skin, Palpable lymphadenopathy etc. ALL is diagnosed by coagulation studies, blood tests, X-Ray, CT-Scan, ECG, MRI, bone marrow aspiration and biopsy etc. Treatment of ALL includes induction chemotherapy, consolidation chemotherapy, Stem cell transplantation and others. A sample of this report is available upon request @ Segmentation: By Trial Phase, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
By Company, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
By Drugs, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
By Route of Administration, Acute Lymphoblastic Leukemia pipeline drugs are segmented as:
Like it? Share it! More by this author |